Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Yan Degenhardt"'
Autor:
Yan Degenhardt, Richard Wooster, Kurt Bachman, Sylvie Laquerre, Christopher Moy, Theresa Conway, Elizabeth McNeil, Xiping Zhang, Aidan Gilmartin, Joanna Dawn Holbrook, Joel Greshock, Junping Jing
The MEK1 and MEK2 inhibitor GSK1120212 is currently in phase II/III clinical development. To identify predictive biomarkers, sensitivity to GSK1120212 was profiled for 218 solid tumor cell lines and 81 hematologic malignancy cell lines. For solid tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f535d971de5d2be79a1ff210de310a7
https://doi.org/10.1158/1535-7163.c.6535302
https://doi.org/10.1158/1535-7163.c.6535302
Autor:
Yan Degenhardt, Richard Wooster, Kurt Bachman, Sylvie Laquerre, Christopher Moy, Theresa Conway, Elizabeth McNeil, Xiping Zhang, Aidan Gilmartin, Joanna Dawn Holbrook, Joel Greshock, Junping Jing
PDF file - 388K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43effdaca1de7e9b68de5fb25b60c4bc
https://doi.org/10.1158/1535-7163.22496511.v1
https://doi.org/10.1158/1535-7163.22496511.v1
Autor:
Richard Wooster, Barbara Weber, Jeffrey Jackson, Kurtis Bachman, Scott Powers, Nancy Liu-Sullivan, Christopher Moy, Ashley Hughes, Wendy Halsey, Maureen Bleam, Xiping Zhang, Mark Richter, Junping Jing, Aidan G. Gilmartin, Sylvie Laquerre, Joel Greshock, Yan Degenhardt
Supplementary Tables 1-5 from Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::473cc85ee7dc604cf29a7644dabe7a47
https://doi.org/10.1158/1535-7163.22485417.v1
https://doi.org/10.1158/1535-7163.22485417.v1
Autor:
Richard Wooster, Barbara Weber, Jeffrey Jackson, Kurtis Bachman, Scott Powers, Nancy Liu-Sullivan, Christopher Moy, Ashley Hughes, Wendy Halsey, Maureen Bleam, Xiping Zhang, Mark Richter, Junping Jing, Aidan G. Gilmartin, Sylvie Laquerre, Joel Greshock, Yan Degenhardt
Supplementary Figure 1 from Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1217c9149d49a2333517ac575554062e
https://doi.org/10.1158/1535-7163.22485420.v1
https://doi.org/10.1158/1535-7163.22485420.v1
Autor:
Richard Wooster, Barbara Weber, Jeffrey Jackson, Kurtis Bachman, Scott Powers, Nancy Liu-Sullivan, Christopher Moy, Ashley Hughes, Wendy Halsey, Maureen Bleam, Xiping Zhang, Mark Richter, Junping Jing, Aidan G. Gilmartin, Sylvie Laquerre, Joel Greshock, Yan Degenhardt
Polo-like kinases are a family of serine threonine kinases that are critical regulators of cell cycle progression and DNA damage response. Predictive biomarkers for the Plk1-selective inhibitor GSK461364A were identified by comparing the genomics and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e7fda7b24c38172397f250024d48998
https://doi.org/10.1158/1535-7163.c.6531924.v1
https://doi.org/10.1158/1535-7163.c.6531924.v1
Autor:
BaoChau Le, Robert L. Vessella, Anastasia Wyce, Peter J. Tummino, Caretha L. Creasy, Susan Korenchuk, Yuchen Bai, Yan Degenhardt, Olena Barbash, Ming-Chih Crouthamel, Charles F. McHugh
Publikováno v:
Oncotarget
BET (bromodomain and extra-terminal) proteins regulate gene expression through their ability to bind to acetylated chromatin and subsequently activate RNA PolII-driven transcriptional elongation. Small molecule BET inhibitors prevent binding of BET p
Autor:
Yan Degenhardt, Richard Wooster, Andrew C. Wood, Patrick A. Mayes, Elizabeth A. Haglund, Sharon J. Diskin, John M. Maris, Christopher Moy, Yana Toporovskya
Publikováno v:
International Journal of Cancer. 132:E149-E157
Inhibition of centromere-associated protein-E (CENP-E) has demonstrated preclinical anti-tumor activity in a number of tumor types including neuroblastoma. A potent small molecule inhibitor of the kinesin motor activity of CENP-E has recently been de
Autor:
Sylvie Laquerre, Scott Powers, Richard Wooster, Jinyu Li, Nancy Liu-Sullivan, Amy Bakleh, Yan Degenhardt, Despina Siolas, John Marchica, Kenneth Chang, Gregory J. Hannon, Jianping Zhang
Publikováno v:
Oncotarget
RNAi screening holds the promise of systemizing the search for combination therapeutic strategies. Here we performed a pooled shRNA library screen to look for promising targets to inhibit in combination with inhibition of the mitotic regulator polo-l
Autor:
Jorge Barriuso, Sarah P. Blagden, Mohammed M. Dar, Andre T. Brunetto, Thomas A. Lampkin, Richard H. Wilson, David Olmos, Hanine Medani, Alicia Allred, Timothy A. Yap, Deborah A. Smith, Anne B. Taegtmeyer, Douglas Barker, Yan Degenhardt, Johann S. de Bono, Rohini Sharma, Sharon C. Murray
Publikováno v:
Clinical Cancer Research. 17:3420-3430
Purpose: GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1). A phase I study of two schedules of intravenous GSK461364 was conducted. Experimental Design: GSK461364 was administered in escalating doses to patients with solid malig
Autor:
Jia Huang, Joseph R. Testa, Joel Greshock, Ralf Bützow, Yan Wang, Barbara L. Weber, Heini Lassus, Phyllis A. Gimotty, Renee Ward, Yan Degenhardt, Katherine L. Nathanson, Dionyssios Katsaros, Andrew K. Godwin, Lin Zhang, Theresa A. Colligon, George Coukos
Publikováno v:
Genes, Chromosomes and Cancer. 50:606-618
Identification and characterization of underlying genetic aberrations could facilitate diagnosis and treatment of ovarian cancer. Copy number analysis using array Comparative Genomic Hybridization (aCGH) on 93 primary ovarian tumors identified PI3K/A